POPULARITY
8 episodes with chronic myeloid leukemia
8 episodes with chronic myeloid leukemia
7 episodes with chronic myeloid leukemia
3 episodes with chronic myeloid leukemia
2 episodes with chronic myeloid leukemia
3 episodes with chronic myeloid leukemia
2 episodes with chronic myeloid leukemia
2 episodes with chronic myeloid leukemia
6 episodes with chronic myeloid leukemia
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore a series of pivotal advancements and challenges shaping the industry landscape—ranging from scientific breakthroughs to regulatory maneuvers, all underscoring the sector's dynamic evolution. Novartis has made headlines with its investigational drug, Delpacibart Braxlosiran, which successfully met primary endpoints in a Phase 1/2 trial for treating Facioscapulohumeral Muscular Dystrophy (FSHD). This RNA therapy utilizes an antibody-oligonucleotide conjugate to target the DUX4 gene, a significant cause of FSHD. The promising results not only mark a potential therapeutic breakthrough for this debilitating neuromuscular disease but also highlight Novartis' commitment to innovative treatments in rare diseases. In parallel, Enliven Therapeutics has reported positive outcomes from a Phase 1 trial of ELVN-001 for patients with Chronic Myeloid Leukemia (CML), who are heavily pretreated. This small molecule tyrosine kinase inhibitor shows improved efficacy, offering hope for those who have exhausted existing treatment options. As ELVN-001 progresses into later-stage trials, it may significantly enhance therapeutic options and outcomes for CML patients. Regulatory activities remain at the forefront, exemplified by Amgen's engagement with the Duke Clinical Research Institute to defend Tavneos amid an FDA push for market withdrawal. This illustrates the intricate complexity of regulatory processes and the importance of evidence-based advocacy in preserving access to critical therapies. In another regulatory development, Guardant Health's Guardant360 CDx has received FDA approval as a companion diagnostic for Boehringer Ingelheim's Hernexeos targeting HER2-mutant non-small cell lung cancer. The approval emphasizes the growing significance of liquid biopsy technologies in personalized oncology care, offering precise and less invasive diagnostic solutions. In business development news, strategic collaborations are gaining momentum. Simcere Pharmaceutical has partnered with Stanford Medicine to develop first-in-class therapies for Idiopathic Pulmonary Fibrosis. Meanwhile, Ildong Pharmaceutical and Welt are joining forces to create AI-driven digital therapeutics. These alliances reflect an increasing trend towards integrating cutting-edge technology and cross-disciplinary expertise to accelerate drug discovery and development. Funding dynamics within the sector are evolving, as seen with Neion Bio's successful Series A fundraising of $23 million aimed at enhancing its biologics manufacturing platform. Similarly, Human Continuum secured $5.13 million to advance its exosome-based regenerative medicine platform. These investments underscore a strong focus on innovative platform technologies promising to transform therapeutic modalities and manufacturing processes. Not all news is positive, however; Jazz Pharmaceuticals and PharmaMar faced setbacks as their Phase 3 trial for Zepzelca (Lurbinectedin) failed to meet its overall survival endpoint in metastatic small cell lung cancer. This highlights the inherent challenges in oncology drug development and underscores the need for continuous innovation. Regulatory hurdles persist as well, evidenced by Camurus receiving a second complete response letter from the FDA regarding Oclaiz (Octreotide) due to manufacturing concerns. The industry is also navigating cybersecurity challenges, as seen with Novo Nordisk's recent data breach incident. This breach underscores vulnerabilities within biopharma companies concerning intellectual property and patient data protection. It serves as a stark reminder of the necessity for robust cybersecurity measures to safeguard sensitive information critical to clinical trials and corporate integrity. Meanwhile, strategic planning remains essential as Astellas confronts a looming $6 billion patent cliff with Xtandi, its prostate cancer drug. The company's five-year strategy focuses on cost savings while sustaining innovation and competitiveness amidst impending revenue declines. The biotechnology sector continues to thrive amidst these challenges, evidenced by record levels of initial public offerings (IPOs). Despite broader economic uncertainties, investor confidence remains robust, highlighting biotech's potential for groundbreaking advancements and lucrative returns. Finally, artificial intelligence is making significant strides across health agencies, with a reported 148% increase at the FDA by 2025 alone. This surge in AI integration highlights its transformative potential in regulatory processes and healthcare delivery—offering opportunities to enhance efficiency and decision-making within the sector. In summary, today's developments encapsulate the vibrant pharmaceutical and biotech industries characterized by scientific innovation, regulatory intricacies, strategic collaborations, and financial maneuvers. These advancements offer new hope for patients while navigating complex landscapes that demand continuous innovation and compliance—a balance that defines success in this ever-evolving sector.Support the show
Welcome to the Oncology Brothers podcast! In this episode, we dived into the complexities of chronic myeloid leukemia (CML) through two challenging case studies. Joined by CML experts Dr. Fadi Haddad from MD Anderson Cancer Center and Dr. Gaby Hobbs from Massachusetts General Hospital, Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ we talked about: The initial workup for diagnosing CML, including the importance of CBC, bone marrow biopsy, and BCR-ABL testing. How to select the most optimal frontline treatment option amongst many available, considering factors like age, comorbidities, and the goal of treatment-free remission (TFR). The role of first-generation TKI, but also how newer TKIs assist in achieving deeper molecular remissions. Strategies for managing treatment breaks and monitoring patients in remission. The role of ponatinib as a pan-BCR:ABL1 inhibitor effective against all known resistance mutations, including T315I, and the optimized response-based dosing strategy to balance efficacy with safety. Tune in for valuable insights on treatment strategies, patient management, and the latest advancements in CML care. Don't forget to like, subscribe, and share your challenging case scenarios for future discussions! #ChronicMyeloidLeukemia, #CML, #TreatmentFreeRemission, #OncologyBrothers
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of transformative events that underscore the dynamic nature of our industry.First on our radar is Merck's acquisition of Terns Pharmaceuticals for a staggering $6.7 billion. This strategic move is rooted in the looming patent expiration of Keytruda, Merck's blockbuster drug. By acquiring Terns, Merck gains access to a promising chronic myeloid leukemia asset, potentially diversifying its oncology portfolio and offsetting anticipated revenue losses. This acquisition is part of a broader industry trend where companies consolidate and acquire to maintain competitive advantages and ensure pipeline robustness amidst patent challenges.In the diabetes arena, Novo Nordisk is making waves with its triple-G candidate in China, which has shown positive mid-phase trial results. This success could position Novo Nordisk as a formidable player in diabetes treatment, even as it faces competition from Eli Lilly. The development not only strengthens Novo Nordisk's global market position but also exemplifies the growing importance of international collaborations and localized clinical trials in accessing emerging markets.Sarepta Therapeutics' investment in Arrowhead Pharmaceuticals' siRNA assets is beginning to show promise with preliminary data from two siRNA candidates. This indicates a significant shift towards RNA-based therapies in addressing untreatable genetic conditions, emphasizing an innovative pivot towards precision medicine and personalized treatment approaches.Maze Therapeutics has released promising phase 2 data for its lead kidney disease candidate, described by analysts as having "best-in-class potential." Despite this clinical promise, the market's negative reaction resulted in a significant drop in Maze's stock value, highlighting the volatile nature of biotech investments where scientific potential often clashes with financial realities.In obesity treatment research, BrightGene's early-stage data shows an 8% weight loss at eight weeks with its oral dual agonist. This adds to evidence supporting multi-target therapies for complex metabolic disorders like obesity. Meanwhile, Takeda's plan to realize $1.3 billion in cost savings through restructuring aims to streamline operations and fund late-stage drug development, reflecting an industry-wide focus on operational efficiency.The partnership between ICON and Advarra seeks to optimize clinical trial efficiency through a network of connected sites, aligning with broader industry efforts to leverage technology and improve drug development timelines.Turning to UCB's substantial $2 billion investment in a biologics manufacturing facility near its US headquarters in Atlanta, Georgia, this move marks UCB's first major manufacturing footprint in the United States, underscoring its commitment to expanding biologics production capabilities. Biologics are increasingly important due to their potential for treating chronic and genetic conditions, highlighting why UCB's investment is pivotal as it strengthens its position in the US market.Biogen's collaboration with Alteogen involves a $20 million investment to utilize Alteogen's subcutaneous delivery technology for two unnamed biologics. Subcutaneous administration offers improved patient convenience and potentially better therapeutic outcomes compared to traditional intravenous methods.On the regulatory front, ImmunityBio received an FDA warning over promotional claims for Anktiva, their cancer drug. This underscores the critical need for accurate communication in drug marketing. Additionally, CSL updated its Flucelvax label at the FDA's request to include a febrile seizure warning, reflecting ongoing vigilance in post-marketing surveillance.The integration of AI into pharmaceutical operations is accelSupport the show
In this episode, we review the high-yield topic of Chronic Myeloid Leukemia (CML) from the Oncology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks… Sarah: Hi Dr. Cabral. Thank you for all you do! Every time I get a cold or virus I break out in full body hives and it takes my body weeks to reset. I've tried your 21DD but seem to be really sensitive to herbal supplements. (Lots of reactions) Please help! Mohamed: Hey Dr.Cabral, 2 part question. Firstly, how are you? Where are you in terms of your overall well-being. I know you get a lot of baggage trying to help others! Just wanted to let you know You helped me a lot. Thought I'd ask, how is your well-being. My secondary question is about water pH, I have an under sink AquaTru without the alkaline remineralization. I sometimes add mineral drops.. wondering about optimal pH range for water. No Kangen yet haha it's expensive for a college student! Jenny: Hi Dr. Cabral - I know you have given recommendations in the past for the community to look into biological dentists, especially when it comes to removing past fillings, alternatives to root canals, etc. What about for regular 6 month check ups and cleanings? If we continue to go to a "regular" dentist for those visits, what is your recommendation about the dental x-rays they require? Thank you! Anonymous: Hi Dr. Cabral - I have a question about eye health. My father had Glaucoma which eventually led to full blindness. His eye doctor prescribed multiple eye drops to help maintain the eye pressure to help delay the progression, but he was on those for probably 20-30 years (Lumigan, Alphagan, Cosopt). My eye doctor is watching the pressure in my eyes and would like me to begin drops, as the pressure is higher than the "normal" range. I don't want to use drops, but also want to maintain eye health. I follow your protocols, including 2 Omega 3 soft gels and the Daily Vision and Eye Health. Do you have any other recommendations? Is Inflamma Soothe something I should take on an ongoing basis, as well? Thank you for all that you do. Dyan: Hello! Thank you so much for all you do! My boyfriend was diagnosed at 26 with Chronic Myeloid Leukemia, with him being so young there are great chances he will go into remission in five years or so and stop his medication. Doctors say CML is a genetic mutation but I know most cancers are from environmental factors. He's taking 50mg of a TKI inhibitor pill daily (considered chemo). I don't feel confident enough in my knowledge to have him stop his chemo pill just yet, but I know we would both love for him to stop it. What is your thought on Ivermectin for cancers patients? I have read it would respond great with his medication. He is super open to anything I've suggested whether it's diet changes or supplements. What supplements or action should we be sure to take? Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes and Resources: StephenCabral.com/3684 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!
In this week's episode, Blood Associate Editor, Dr. Jason Gotlib leads a discussion about the How I Treat Series commemorating the 25th anniversary of the introduction of tyrosine kinase inhibitors in CML, featuring Drs. Neil Shah, Simona Soverini, Elisabetta Abruzzese, and Yves Chalandon. The introduction of TKIs revolutionized patient outcomes in CML, turning a poor prognosis—3 to 5 years life expectancy—to a manageable chronic condition. In this conversation, we'll cover management techniques for CML during relapse, pregnancy, and explore indications for hematopoietic stem cell transplantation. See the full How I Treat series in Volume 147 issue 4 of Blood.
In this podcast episode, Amir T. Fathi, MD, reviews data from select presentations in leukemias at the ASH 2025 Annual Meeting, and provides perspectives on the clinical implications of these data for patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML), including:Abstract 6: Phase II PARADIGM trial of azacitidine and venetoclax vs conventional intensive chemotherapy for fit patients with newly diagnosed AMLAbstract 47: Phase I/II SAVE trial of revumenib plus decitabine/cedazuridine and venetoclax in the cohort of patients with newly diagnosed AMLAbstract 766: Phase Ib KOMET-007 trial of ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-mutant AMLAbstract 654: Phase I/II VICEROY trial of venetoclax and azacitidine + gilteritinib in patients with newly diagnosed FLT3-mutated AML ineligible for intensive induction chemotherapyAbstract 903: 3-Yr Update of the phase II FASCINATION trial of asciminib and conventional BCR::ABL1 inhibitors in newly diagnosed CMLAbstract 906: Phase II ASC2ESCALATE trial of asciminib in patients with chronic-phase CML after 1 prior TKIPresenter:Amir T. Fathi, MDDirector, Leukemia ProgramMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program:https://bit.ly/48Ye45N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
This podcast has been supported by Novartis In this new podcast episode, Lisa Machado, a patient advocate diagnosed with CML in 2008 and clinician and CML expert Jeffrey Lipton, sit down to explore: How patients and physicians can navigate the shock of diagnosis and information overload. Why aligning treatment goals goes beyond molecular milestones to focus on quality of life. Practical ways to foster trust, encourage open conversations, and strengthen shared decisions. Whether you're supporting newly diagnosed patients or reassessing long-term treatment, this conversation offers fresh insights to improve communication, satisfaction, and outcomes in CML.
In this episode of the Oncology Brothers podcast, we welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss the latest updates in the management of Chronic Myeloid Leukemia (CML). Join us as we dive into the essential aspects of CML treatment, including: • The importance of initial workup and bone marrow biopsy in diagnosing CML. • Risk stratification and the selection of first-line therapies, including the latest TKIs like Asiminib and Ponatinib. • Patient-centered decision-making and how to align treatment options with individual patient goals. • Monitoring for response using BCR-ABL titer and the role of minimal residual disease (MRD). • The significance of managing side effects associated with various TKIs, including cardiovascular risks and unique toxicities. • Insights into the role of transplant in accelerated and blast phases of CML. Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of CML treatment. Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and tune in for more episodes on treatment algorithms, FDA approvals, and conference highlights. #CML #TKIs #Asciminib #Imatinib #Pontatinib #Bosutinib #Dasatinib #Nilotinib #BCR-ABL #Hematology #OncologyBrothers #JorgeCortes
Dr Michael Mauro, Dr Neil Shah, and nurse practitioners Ms Ilene Galinsky and Dr Sara Tinsley-Vance discuss important nursing considerations in the modern treatment of chronic myeloid leukemia. NCPD information and select publications here.
Featuring perspectives from Ms Ilene Galinsky, Dr Michael J Mauro, Dr Neil P Shah and Dr Sara M Tinsley-Vance, including the following topics: Introduction: Chronic Myeloid Leukemia (CML) as a Model for Targeted Treatment (0:00) Biology of CML; Role of First- and Second-Generation Tyrosine Kinase Inhibitors (TKIs) as Initial Treatment for Chronic-Phase (CP) CML (12:37) Role of Asciminib for Newly Diagnosed CP-CML (47:46) Feasibility of TKI Discontinuation for Patients with Sustained Response to Treatment (1:14:06) Management of CP-CML After Failure of Initial Therapy (1:23:04) NCPD information and select publications
Editor's Summary by JAMA Deputy Editors Linda Brubaker, MD, and Preeti Malani, MD, MSJ, for articles published from March 15-21, 2025.
Chronic myeloid leukemia is a myeloproliferative neoplasm that affects approximately 5 million people worldwide. Tyrosine kinase inhibitors, such as imatinib, have substantially improved survival in patients with chronic myeloid leukemia. In this podcast, author Elias J. Jabbour, MD, of the University of Texas MD Anderson Cancer Center, discusses diagnosis and treatment of chronic myeloid leukemia with JAMA Deputy Editor Mary McDermott, MD. Related Content: Chronic Myeloid Leukemia
How do STAMP inhibitors differ from ATP-competitive tyrosine kinase inhibitors (TKIs) when treating chronic myeloid leukemia (CML)? Credit available for this activity expires: 03/13/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/chronic-myeloid-leukemia-2025-update-novel-targets-and-2025a10005pm?ecd=bdc_podcast_libsyn_mscpedu
Featuring perspectives from Prof Andreas Hochhaus, Dr Michael J Mauro and Dr B Douglas Smith, moderated by Dr Mauro, including the following topics: Introduction (0:00) Up-Front Therapy for Chronic Myeloid Leukemia (CML) — Prof Hochhaus (2:45) Management of Relapsed CML, Including in Patients with a T315I Mutation — Dr Mauro (29:23) Tolerability and Other Practical Issues with Commonly Employed CML Therapies — Dr Smith (1:00:15) CME information and select publications
Prof Andreas Hochhaus from Jena University Hospital in Germany, Dr B Douglas Smith from the Sidney Kimmel Comprehensive Cancer Center at John Hopkins in Baltimore, Maryland, and Dr Michael J Mauro from Memorial Sloan Kettering Cancer Center in New York, New York, discuss recent updates on available and novel treatment strategies for chronic myeloid leukemia.
Join host Talaya Dendy on Navigating Cancer TOGETHER as she welcomes Tim Sohn, an 18-year chronic myeloid leukemia (CML) survivor. Tim shares his personal journey, the importance of community building, his involvement in the #SpeakUpCML campaign, and the impact of living with an invisible illness. Don't miss this inspiring conversation filled with hope, resilience, and valuable insights for cancer patients, survivors, and supporters.✨Highlights from the show:02:33 Tim's Cancer Journey and Community Building12:11 Challenges and Mental Health17:19 Support Systems and Resources32:54 Showing Up: Perspectives on CancerTranscript: https://bit.ly/podscript156-2
Prof Andreas Hochhaus from Jena University Hospital in Germany, Dr B Douglas Smith from the Sidney Kimmel Comprehensive Cancer Center at John Hopkins in Baltimore, Maryland, and moderator Dr Michael J Mauro from Memorial Sloan Kettering Cancer Center in New York, New York, discuss recent updates on available and novel treatment strategies for chronic myeloid leukemia. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHCML24).
In this week's episode we'll learn more about the ASCEND study, which investigated first-line asciminib in chronic phase chronic myeloid leukemia; a new risk score for myeloid neoplasm transformation in patients with clonal cytopenia of undetermined significance; and use of RHD genotyped D-positive blood transfusions in patients with sickle cell and unexpected anti-D antibodies.Featured ArticlesAsciminib Monotherapy as Frontline Treatment of Chronic Phase Chronic Myeloid Leukaemia - Results from the ASCEND StudyRisk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence Genotyped RhD+ red cells for D-positive patients with sickle cell disease with conventional RHD and unexpected anti-D
Practical Perspectives: Current Management of Chronic Myeloid Leukemia | Faculty Presentation — Jorge Cortes, MD CME information and select publications
Featuring perspectives from Dr Bhavana (Tina) Bhatnagar, Dr Amanda Blackmon, Dr Jorge Cortes, Dr Michael J Mauro and Dr Neil P Shah, including the following topics: Recently presented data affecting the treatment of newly diagnosed chronic myeloid leukemia (CML) (0:00) Case: A man in his mid 40s with newly diagnosed CML with tyrosine kinase inhibitor (TKI) tolerability issues but a good response (24:51) Case: A woman in her mid 80s with chronic-phase CML (CP-CML) with translocation (9;22) (40:26) Case: A woman in her mid 80s with CP-CML and notable comorbidities (43:12) Case: A woman in her early 50s with CP-CML intolerant to dasatinib (51:22) Case: A woman in her late 50s with CP-CML and TKI withdrawal syndrome (1:01:22) Case: A woman in her mid 50s with accelerated-phase CML (1:08:22) Case: A woman in her early 70s with CP-CML and a suboptimal response to second-line TKI (1:17:00) Case: A man in his mid 30s with CP-CML and a complex variant Ph-positive translocation (1:23:24) Case: A man in his mid 30s with CP-CML and a T315I mutation (1:28:55) CME information and select publications
Drs Bhavana (Tina) Bhatnagar, Amanda Blackmon, Jorge Cortes, Michael J Mauro and Neil P Shah discuss recent updates on clinical treatment strategies for chronic myeloid leukemia.
Drs Bhavana (Tina) Bhatnagar, Amanda Blackmon, Jorge Cortes, Michael J Mauro and Neil P Shah discuss recent updates on clinical treatment strategies for chronic myeloid leukemia, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/CML2024/CaseRoundtable).
Join the Oncology Brothers, Drs. Rahul and Rohit Gosain, as they dive into the world of Chronic Myeloid Leukemia (CML) with world-renowned hematologist Dr. Jorge Cortes from the Georgia Cancer Center. In this episode, they discuss the current standard of care treatment options for CML, including risk stratification, monitoring, treatment algorithms, and side effects of first, second, and third-generation TKIs. Dr. Cortes provides valuable insights on when to consider treatment holidays, switching therapies, and the potential benefits of upcoming treatments like asciminib. The discussion also covers the importance of deep molecular responses, the role of bone marrow biopsies, and the decision-making process for patients in accelerated phase CML. Tune in to gain a comprehensive understanding of managing CML patients in the community setting and stay updated on the latest advancements in hematology and oncology. Don't miss out on this informative episode with the Oncology Brothers podcast! Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com
Primary results from ASC4FIRST trial, the first study in chronic myeloid leukemia comparing current standard-of-care frontline tyrosine kinase inhibitors with the novel agent asciminib in newly diagnosed patients, were reported at the 2024 ASCO Annual Meeting. First author Timothy Hughes MD, Consultant Hematologist with the Royal Adelaide Hospital, the South Australian Health and Medical Research Institute, and the University of Adelaide in Australia, reported higher efficacy in terms of major molecular responses and lower toxicity with asciminib. After his talk in Chicago, he met up with Oncology Times reporter, Peter Goodwin.
Josh “Juice” Little – Essington. In his early 20's, Josh was diagnosed and defeated Hodgkin's Lymphoma. Three cancer-free years went by, but there were always intrusive thoughts that it could return. Sadly, in October of last year, that did happen, and it came back in the form of Chronic Myeloid Leukemia. Thanks to advancements and specialized treatment that can be provided in this area surrounding Delco, Josh is managing the diagnosis with some cutting-edge therapy, and the prognosis is excellent. Josh is an icon of South Delco, from one of the most entertaining families in the County, and has helped with several Delco Days in the past. It is an honor to make him one of the Benefactors of this year's installment. www.DelcoLive.com
When Tim Sohn spotted some unusual bruises on one of his legs, he sought medical attention. This led to hospitalization and a subsequent diagnosis of a form of blood cancer, chronic myeloid leukemia. With the aid of two types of oral chemotherapy, Tim survived. His experience inspired him to help others diagnosed with cancer, in the form of a book and a live podcast. This is his story.
Serghei Tvetcov is living with Leukemia. He was diagnosed with cancer in September 2022. He was racing with his Wildlife Generation Pro Cycling Team in the Tour of Romania when he got the results. He says he knew something wasn't right. Tvetcov simply couldn't put out the numbers he was used to doing. So he went and got tested. The test revealed he was living with Chronic Myeloid Leukemia. He says the result were a kick in the head. For treatment he takes chemo directed pills twice a day. Every three months he has a genetic test that shows him his response to the meds. He says it's a cancer that's not curable rather it's something he'll live with for the rest of his life. Tvetcov says he plans to race in 2024. His plans include racing gravel and spreading a message of survival. He wants folks who have the same disease to know you can live and thrive while living with Chronic Myeloid Leukemia. Also in this episode we also touch on his start in cycling, coming to America, racing in Italy, and France. And racing for the famous Gianni Savio.
Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks… Shelley: Hi Dr. Cabral. I love you and your work. Thank you. My question is about my daughter who was diagnosed with JRA at the age of 13. She has been on various meds and is currently on Humira to control her symptoms. She has had a positive ANA test and a Centromere B ab of 1.4 which is high. Her doctor is concerned about CREST among other things. She also has had Myastenia Gravis. All serious auto immune diseases. She tries to be gluten free and careful with her diet but as an 18 year old going to college, I am concerned. What advice might you have to get control of this auto immune nightmare? Thank you for all you do. Lindsey: hi dr. cabral! thank you for this podcast and all of your knowledge. i have 2 questions for you — 1.i run a body fever most nights. i notice it significantly when i lay down to go to sleep and my partner says i'm literally radiating heat. i suspect my body is trying to fight off something - what do you suggest as a first step in finding the root cause?2. my heart races/gets faster after meals (whether it be healthy or unhealthy food). can you help?thank you Tiffany: Ive listened to your podcast for 10 yrs & am grateful for your passion your knowledge & helping people. Question: An older friend of mine had to have emergency surgery to remove a non cancerous infected mass from her bowl & has been on a constant antibiotic drip for 2 wks. The I.V. was just removed & she is home w/a drainage bag still attached outside of her body to help rid the infection. When I found this out, I immediately ordered for her the Clean Gut Pros, Saccharomysis Boulardii & a 7 day detox. I was also able to talk her into The Big 5, to get the root cause. She then mentioned she also has Chronic Myeloid Leukemia. I tried to research your podcasts for info on this with no luck. Lab results will soon reveal but want any advice on CML to be in your podcasts. Much appreciated! Mandy: Hi doctor Cabral, I've been following your work, and listening to your podcast for years, and it has truly changed by health for better, so I'm eternally grateful. I have a question about my parents: they are both in their mid-70s and I want to keep them as healthy as possible. What are some essential supplements that they should definitely be using? They are not on anything now. They both eat pretty healthy and walk around 20K steps a day. Thanks so much for your advice! Erika: Breast question (I have a dr appointment next week and i know it will be weeks until you get to this but that's okay, would love your opinion)….we did a lot of hiking in the mountains 2 weeks ago and i had a backpack on. After the 5th day, at the end of the day i noticed one breast on the underside looked bruised or like the veins were widened and very visible. I've never had this before…. The blue color will be very light in the morning but after exercising it's back darker again. And only on the underside of the boob.Any idea what is happening? Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes and Resources: StephenCabral.com/2816 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!
Nourishing your body after a cancer diagnosis can seem like an impossible task when your mind is focused on survival.… The post Fueling Hope: Nutrition Insights for Chronic Myeloid Leukemia (CML) appeared first on The Bloodline with LLS.
Nourishing your body after a cancer diagnosis can seem like an impossible task when your mind is focused on survival.… The post Fueling Hope: Nutrition Insights for Chronic Myeloid Leukemia (CML) first appeared on The Bloodline with LLS.
Are you currently facing adversity? How are you coping while navigating life's challenges? In this week's episode, we have an interview with Frank McKinney, who successfully fought and overcame Chronic Myeloid Leukemia. He is now two years cancer-free and has written a book about his experience and how he conquered one of the greatest adversities in his life. After listening to this episode, you will definitely want to buy the book as it not only offers valuable insights but also can help an entire village in Haiti. Key takeaways from the episode: Adversity can make you feel dead inside, so take risks and do something that makes you feel most alive. Your adversity has a purpose. Do not hold onto the past or difficult times because tomorrow is a new day. Do not become a victim of "Stockholm Syndrome" when facing adversity. Acknowledge it and do not let it consume you.
Join us as we hear two different perspectives from people living with chronic myeloid leukemia (CML); Tim Sohn, a 16-year… The post Perspectives on Quality of Life: Chronic Myeloid Leukemia (CML) first appeared on The Bloodline with LLS.
Join us as we hear two different perspectives from people living with chronic myeloid leukemia (CML); Tim Sohn, a 16-year… The post Perspectives on Quality of Life: Chronic Myeloid Leukemia (CML) appeared first on The Bloodline with LLS.
Alexa Score is a professional wakeboarder, TV host, speaker, and cancer survivor. Born and raised in small town Spicer, Minnesota, she hails from humble Midwestern roots, and now splits time between Orlando, Florida and Minneapolis, Minnesota.She has represented numerous global brands including Liquid Force, Hard Rock Cafe, LifeProof, SPY Optic, Body Glove, and others. She has appeared in print and video ads across the globe and has a plethora of experience in the TV and film industries, including being a TV personality on networks such as MTV, ESPN, and Travel Channel, and appearing in the SyFy movie: Two Headed Shark Attack. She's currently a TV personality for the Minnesota Vikings, cohost of Made for the Outdoors (Sportsman Channel and Fox Sports Networks), cohost of Destination Polaris (Fox Sports Networks), and a member of The CW Twin Cities on-air crew. Alexa was diagnosed with Chronic Myeloid Leukemia at age sixteen and has been living with cancer for the past thirteen years. Her journey is far from over as she continues to battle her disease and its side effects. She uses her platform to raise money and awareness for multiple charities including: The Leukemia & Lymphoma Society, BeTheMatch.org, and others. Despite dealing with the constant side affects of cancer and treatment, Alexa has made it a priority to live an active, energetic, and healthy lifestyle.Alexa is a life force and inspiration to others, it was such an honor to have her on the show! Listen now on A Juicy Pear Podcast. If your feeling lead, you can Buy Me A Coffee on http://www.ajuicypearpodcast.comSupport the show
Join us as we speak to Dr. Richard Larson and Dr. Anand Patel from University of Chicago Medicine about chronic… The post Hopeful Advancements for Chronic Myeloid Leukemia (CML) first appeared on The Bloodline with LLS.
Join us as we speak to Dr. Richard Larson and Dr. Anand Patel from University of Chicago Medicine about chronic… The post Hopeful Advancements for Chronic Myeloid Leukemia (CML) appeared first on The Bloodline with LLS.
Ehab Atallah, MD, Medical College of Wisconsin, Milwaukee, WI Recorded on January 24, 2023 In this episode, Dr. Ken Miller sits down with Dr. Ehab Atallah, from the Medical College of Wisconsin, to discuss chronic myeloid leukemia (CML) including the development of tyrosine kinase inhibitors (TKIs), challenges with adherence to treatment, side effect management, and long-term and late effects, including cardiac toxicities. Dr. Atallah describes the work of the H. Jean Khoury Cure CML Consortium, shares his insights in to transitioning patients off TKIs, experience with his patients living with measurable residual disease, and excitement about the future of CML therapy. Learn more by tuning in today!
Dr Bill Nelson speaks with Lindsey Ledwin, a patient diagnosed with Chronic Myeloid Leukemia in 2018, and Dr Tania Jain one of her oncologists, about her cancer journey and advocacy for other patients being treated at the Johns Hopkins Kimmel Cancer Center.
Today we are joined by Becky Dame, currently an Information Specialist at The Leukemia & Lymphoma Society, RN and Survivor. As Peggy says in the podcast, callers who end up talking to Becky must feel like they've hit the information jackpot. Becky is a chronic myeloid leukemia (CML) survivor who went on to become a cancer care nurse, before she transitioned to her current role. Today, we tap into her wealth of personal and professional experience.Becky was diagnosed as a college student in 1991, and received her first bone marrow transplant in 1992. At this time, she felt called to be a nurse and changed from a music major to nursing school, marrying her husband on the day she graduated. For 18 years, she went through cycles of relapse, always on the lookout for the newest treatments for her disease. Then, in 2010, she received a matched unrelated donor (MUD) transplant, and was able to break that cycle. Today, however, Becky battles Graft vs. Host Disease (GVHD).In 2017, she joined The Leukemia & Lymphoma Society, where she says it's her goal to share her "pearls" of wisdom with patients, caregivers, and anyone else that she can find commonalities with. Becky speaks to the importance of finding a primary caregiver --transplant is not a journey you can go at alone. Also, plan to be out of work for at least a year - and we cover some resources available to patients. There are also practical tips in today's podcast, such as why wearing a button-up shirt to the hospital can be a clutch move.Finally, Becky reflects on her journey, saying there's nothing she would change, feeling like everything happens for a reason, and now she's here to help others.The Leukemia & Lymphoma Society for One-on-One Supporthttps://www.lls.org/patient-support, 1-800-955-4572Other ResourcesNational Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKnbmtLINK YouTube Page can be found by clicking here.Thank you to this season's sponsors:The Leukemia & Lymphoma Society, www.lls.orgSanofi: https://www.sanofi.com/
This week's episode will be focusing on Chronic Myeloid Leukemia or CML for health care providers. We will go all the important details on the genetics of CML, diagnosis and treatment algorithms.
In this episode, we review the high-yield topic of Chronic Myeloid Leukemia (CML) from the Oncology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://anchor.fm/medbulletsstep1/message
To acknowledge the Philadelphia Chromosome translocation t(9;22) in chronic myeloid leukemia (CML), every September 22 (9/22) is World CML Day. Today's podcast episode looks at this topic through different lenses. First, two members of the Lancet Haematology's committee on adverse events—Jan Geissler, co-founder of the CML Advocates Network, and Gita Thanarajasingam, MD, the committee chair and a hematologist at the Mayo Clinic—discuss how side effects are reported and analyzed and how the committee intends to change that. Geissler also talks about how his experience as a patient with CML led him to become and expert advocate. Additional reading:Geissler J, Huber S. Improving outcomes through patient-generated evidence-the next step in patient advocacy. Lancet Haematol. 2022 Jun;9(6):e399-e400. Thanarajasingam G, et al. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2022 May;9(5):e374-e384Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA. 2017 Jul 11;318(2):197-198.
Maggie and I go way back (like... to middle school) and we've only reconnected after all these years due to having something very personal in common... cancer as a young adult. Her story is UN-BE-LIEVE-ABLE. She tells us about being diagnosed so young, her battle with Chronic Myeloid Leukemia, surviving a bone marrow transplant, getting a new birthday and so much more.SUPPORT THE SHOWPODCAST/CANCER MERCH: Visit facingfearwithsara.com/merchCATCH UP ON MY CANCER JOURNEY: facingfearwithsara.com/episodesCONNECT With the guest, @hardintomaggieSubscribe to the monthly newsletter at facingfearwithsara.comInstagram - @facingfearwithsara, @saramcinerneyhauckTikTok - @facingfearwithsaraFacebook - @facingfearwithsaraWebsite - facingfearwithsara.comYouTube - Sara McInerney HauckEmail - hello@facingfearwithsara.com Support the show
Featuring perspectives from Dr Daniel DeAngelo, including the following topics: Introduction: Perspectives on chronic myeloid leukemia (CML) (0:00) Asciminib — ASC4FIRST study (8:33) Case: A woman in her early 60s with a PMH of Stage IA hormone receptor-positive breast cancer on adjuvant tamoxifen with newly diagnosed CML — Michael R Grunwald, MD (22:38) Case: A man in his mid 40s with low-risk CML who achieves MR4 on imatinib but loses molecular response 3 months after discontinuing therapy — Shams Bufalino, MD (27:23) Case: A man in his early 40s with CML on dasatinib who does not achieve treatment milestone (MR3) at 18 months but does at 24 months — Dr Grunwald (33:19) Case: A man in his early 80s with CML who initially receives imatinib followed by nilotinib develops CHF and has a BCR-ABL of 0.8% (IS) — Namrata I Peswani, MD (37:33) Case: A woman in her late 20s with CML that is resistant to multiple TKIs and therapy compliance concerns — Minesh Dinubhai Patel, MD (40:44) Case: A woman in her early 40s who initially receives dasatinib for chronic-phase CML with a good response but then develops lymphoid blast crisis — Dr Grunwald (52:17) Case: A woman in her mid 70s with CML who achieves MMR on nilotinib but then develops peripheral arterial occlusion after 9 years on therapy — Dr Grunwald (58:10) CME information and select publications
Featuring a discussion on the treatment of chronic myeloid leukemia with Dr Daniel DeAngelo, moderated by Dr Neil Love.
Featuring perspectives from Dr Jorge Cortes, including the following topics: Introduction: Journal Club with Dr Cortes (0:00) Case: A man in his early 40s with chronic myeloid leukemia (CML) and osteopenia after long-term imatinib therapy — Rajalaxmi McKenna, MD (15:00) Case: A man in his early 60s with chronic phase CML (CP-CML) and continued detectable BCR-ABL transcript on bosutinib — Bruce Bank, MD (23:55) Case: A man in his early 70s with CP-CML and notable toxicities from several BCR-ABL tyrosine kinase inhibitors (TKIs) — Gigi Chen, MD (27:37) Case: A woman in her late 40s with CML in complete molecular response for more than 3 years with nilotinib — Michael R Grunwald, MD (36:05) Case: A woman in her mid 60s with CP-CML and negative BCR-ABL mutational analyses who experiences lack of disease response to several BCR-ABL TKIs — Shams Bufalino, MD (43:27) Case: A man in his early 40s with CP-CML who is found to have a T315I mutation — Dr Grunwald (44:45) Appendix of Key Recent Data Sets (53:26) CME information and select publications
Featuring a discussion on the treatment of chronic myeloid leukemia with Dr Jorge Cortes, moderated by Dr Neil Love.
In this episode, we review the high-yield topic of Chronic Myeloid Leukemia (CML) from the Oncology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial
© 2020-2026 Ivy Podcast Discovery LLC
